Wall Street analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report sales of $25.30 million for the current quarter, Zacks reports. Three analysts have made estimates for Oxford Immunotec Global PLC’s earnings. The lowest sales estimate is $25.20 million and the highest is $25.43 million. Oxford Immunotec Global PLC posted sales of $19.15 million in the same quarter last year, which would indicate a positive year over year growth rate of 32.1%. The firm is expected to issue its next quarterly earnings results before the market opens on Tuesday, August 1st.

According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full-year sales of $25.30 million for the current fiscal year, with estimates ranging from $103.39 million to $104.88 million. For the next year, analysts expect that the business will report sales of $121.24 million per share, with estimates ranging from $118.27 million to $123.00 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Oxford Immunotec Global PLC.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its earnings results on Tuesday, May 2nd. The company reported ($0.36) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Oxford Immunotec Global PLC had a negative return on equity of 31.48% and a negative net margin of 25.83%. The business had revenue of $21.51 million for the quarter, compared to analysts’ expectations of $21.17 million.

A number of research firms have recently issued reports on OXFD. Zacks Investment Research cut Oxford Immunotec Global PLC from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. ValuEngine upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BTIG Research reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Thursday, May 4th.

Oxford Immunotec Global PLC (OXFD) opened at 16.31 on Friday. The company’s 50-day moving average price is $15.71 and its 200 day moving average price is $14.80. The stock’s market capitalization is $373.92 million. Oxford Immunotec Global PLC has a 52-week low of $7.73 and a 52-week high of $17.38.

In other news, insider Jeff R. Schroeder sold 40,000 shares of the business’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $14.14, for a total value of $565,600.00. Following the completion of the sale, the insider now owns 149,544 shares of the company’s stock, valued at approximately $2,114,552.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Peter Wrighton-Smith sold 27,168 shares of the business’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $15.94, for a total value of $433,057.92. Following the completion of the sale, the chief executive officer now directly owns 488,836 shares of the company’s stock, valued at approximately $7,792,045.84. The disclosure for this sale can be found here. In the last three months, insiders sold 147,085 shares of company stock valued at $2,275,928. 7.58% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors raised its stake in Oxford Immunotec Global PLC by 1.9% in the first quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after buying an additional 254 shares during the period. American International Group Inc. raised its stake in Oxford Immunotec Global PLC by 7.1% in the first quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after buying an additional 904 shares during the period. TFS Capital LLC raised its stake in Oxford Immunotec Global PLC by 19.8% in the first quarter. TFS Capital LLC now owns 14,125 shares of the company’s stock worth $219,000 after buying an additional 2,337 shares during the period. Teachers Advisors LLC raised its stake in Oxford Immunotec Global PLC by 15.7% in the first quarter. Teachers Advisors LLC now owns 46,200 shares of the company’s stock worth $716,000 after buying an additional 6,268 shares during the period. Finally, Denver Investment Advisors LLC raised its stake in Oxford Immunotec Global PLC by 47.5% in the first quarter. Denver Investment Advisors LLC now owns 30,880 shares of the company’s stock worth $478,000 after buying an additional 9,949 shares during the period. 87.53% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Oxford Immunotec Global PLC (OXFD) Will Announce Quarterly Sales of $25.30 Million” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.americanbankingnews.com/2017/07/22/analysts-anticipate-oxford-immunotec-global-plc-oxfd-will-announce-quarterly-sales-of-25-30-million.html.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.